Latest news

• Bayer moves vilaprisan into phase III trials for uterine fibroids

  Bayer is beginning late-stage trials of vilaprisan, its novel oral, selective progesterone receptor modulator (SPRM) treatment for women with uterine fibroids. ... The three-year, phase III ASTEROID study will investigate the efficacy and safety of 2mg

• Xarelto and Eylea continue to dominate Bayer's pharma sales

  They include five candidates in phase III trials: copanlisib for non-Hodgkin lymphoma, ODM-201 for hormone-sensitive prostate cancer, finerenone for diabetic kidney disease, vilaprisan for uterine fibroids and endriametosis

• Allergan plans to file oral uterine fibroid drug in US by year-end

  Other companies working on new therapies for uterine fibroids include Bayer, which has a candidate called vilaprisan in mid-stage clinical development.

• Allergan on course to file uterine fibroid drug next year

  Other companies working on new therapies for uterine fibroids include Bayer, which has a candidate called vilaprisan in mid-stage clinical development.

• Bayer puts research at heart of business growth

  The other two drugs touted to advance to phase III are copanlisib for non-Hodgkin's lymphoma and vilaprisan to treat symptomatic uterine fibroids – begin tumours that form in the uterus.